Werewolf Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.14 Insider Own18.45% Shs Outstand29.76M Perf Week-2.75%
Market Cap51.45M Forward P/E- EPS next Y-1.63 Insider Trans0.00% Shs Float25.07M Perf Month-37.68%
Income-59.70M PEG- EPS next Q-0.59 Inst Own77.10% Short Float / Ratio0.52% / 1.38 Perf Quarter-74.46%
Sales9.10M P/S5.65 EPS this Y-621.50% Inst Trans9.24% Short Interest0.13M Perf Half Y-58.55%
Book/sh4.40 P/B0.40 EPS next Y20.10% ROA-34.60% Target Price16.50 Perf Year-87.38%
Cash/sh4.83 P/C0.37 EPS next 5Y19.10% ROE-43.20% 52W Range1.62 - 15.89 Perf YTD-85.14%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-88.86% Beta-
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low8.92% ATR0.23
Employees48 Current Ratio5.50 Sales Q/Q- Oper. Margin- RSI (14)24.11 Volatility8.39% 11.94%
OptionableYes Debt/Eq0.00 EPS Q/Q20.60% Profit Margin- Rel Volume2.45 Prev Close1.84
ShortableYes LT Debt/Eq0.00 EarningsNov 10 BMO Payout- Avg Volume93.34K Price1.77
Recom1.20 SMA20-13.18% SMA50-45.49% SMA200-61.77% Volume229,005 Change-3.80%
Sep-10-21Initiated BofA Securities Buy $26
May-25-21Initiated SVB Leerink Outperform $29
May-25-21Initiated Jefferies Buy $22
May-25-21Initiated H.C. Wainwright Buy $32
May-25-21Initiated Evercore ISI Outperform $23
Nov-10-22 09:00AM
Nov-07-22 04:05PM
Sep-07-22 07:00AM
07:00AM Loading…
Sep-01-22 07:00AM
Aug-15-22 06:45AM
Aug-11-22 07:00AM
Aug-03-22 07:00AM
Jul-05-22 07:54AM
Jun-06-22 04:51PM
May-10-22 07:00AM
Apr-08-22 02:29PM
Apr-07-22 09:25AM
08:34AM Loading…
Mar-24-22 07:00AM
Mar-16-22 08:00AM
Mar-15-22 08:00AM
Feb-08-22 08:00AM
Jan-26-22 06:53AM
Jan-05-22 08:00AM
Dec-14-21 04:01PM
Dec-01-21 08:00AM
Nov-10-21 07:00AM
Nov-08-21 08:03AM
Oct-28-21 04:01PM
Oct-27-21 07:30AM
Sep-14-21 08:00AM
08:00AM Loading…
Sep-08-21 08:00AM
Aug-19-21 10:57AM
Aug-18-21 07:30AM
Aug-12-21 07:00AM
Jul-30-21 05:03AM
Jun-24-21 07:00AM
Jun-18-21 09:16PM
Jun-15-21 07:00AM
Jun-10-21 07:00AM
May-27-21 07:30AM
May-21-21 07:41PM
Apr-30-21 04:44PM
Apr-29-21 09:19PM
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seidel-Dugan CynthiaChief Scientific OfficerJan 12Option Exercise2.8139,731111,838164,888Jan 14 05:58 PM
Leonard ReidChief Operating OfficerDec 15Sale13.413,00040,242122,157Dec 17 04:17 PM